Page Michelle E, Brown Kevin, Lucki Irwin
Current address: Department of Neurobiology and Anatomy, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, USA.
Psychopharmacology (Berl). 2003 Jan;165(2):194-201. doi: 10.1007/s00213-002-1269-x. Epub 2002 Nov 9.
The forced swimming test (FST) is a rodent behavioral assay widely used to predict clinical efficacy of putative antidepressants. Few studies have examined the effects of the FST on neurotransmitter levels and how antidepressant drug treatment may alter neurotransmitter levels and behavior simultaneously during the performance of a stressful task.
The present study examined the role of norepinephrine in mediating active behaviors in the FST after treatment with reboxetine, a selective norepinephrine reuptake inhibitor.
High-pressure liquid chromatography was used to analyze microdialysis samples collected from awake, freely moving rats before, during and after exposure to the FST. Reboxetine (10 mg/kg) was given three times over a 24-h period prior to the test swim. Behavioral responses, including immobility, swimming and climbing, were counted during the 5-min test on day 1 and day 2.
The first exposure to swim stress elicited a 65% increase in extracellular norepinephrine (NE). A second exposure on day 2 elicited a 52% increase of NE and a behavioral profile characterized by increased immobility and a reduction of active behaviors. A subchronic course (three injections over 24 h) of treatment with reboxetine between the two swim exposures resulted in antidepressant-like activity, i.e., decreased immobility and increased climbing behavior on day 2. A significantly greater increase in extracellular NE (112%) was observed in the group of animals that received reboxetine injections.
Treatment with reboxetine in a schedule commonly used in the FST resulted in a potentiated noradrenergic response to the swim challenge concomitant with behavioral alterations consistent with antidepressant-like activity.
强迫游泳试验(FST)是一种啮齿动物行为测定方法,广泛用于预测假定抗抑郁药的临床疗效。很少有研究考察FST对神经递质水平的影响,以及抗抑郁药物治疗如何在应激任务执行过程中同时改变神经递质水平和行为。
本研究考察了去甲肾上腺素在瑞波西汀(一种选择性去甲肾上腺素再摄取抑制剂)治疗后介导FST中主动行为的作用。
采用高压液相色谱法分析在清醒、自由活动的大鼠暴露于FST之前、期间和之后收集的微透析样本。在测试游泳前24小时内,瑞波西汀(10mg/kg)给药三次。在第1天和第2天的5分钟测试期间,统计行为反应,包括不动、游泳和攀爬。
首次暴露于游泳应激导致细胞外去甲肾上腺素(NE)增加65%。第2天的再次暴露导致NE增加52%,行为特征为不动增加和主动行为减少。在两次游泳暴露之间进行瑞波西汀亚慢性疗程(24小时内注射三次)治疗产生了抗抑郁样活性,即第2天不动减少和攀爬行为增加。在接受瑞波西汀注射的动物组中,观察到细胞外NE显著更大幅度的增加(112%)。
按照FST中常用的给药方案使用瑞波西汀治疗,导致对游泳挑战的去甲肾上腺素能反应增强,同时伴有与抗抑郁样活性一致的行为改变。